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1139-47 Drug-Eluting Stent With Multidimensional 
Programmable Pharmacokinetics
Colin T. Watanabe, Joseph Aragon, Saibal Kar, Ted Parker, Frank Litvack, Neal L. Eigler, 
Cedars-Sinai Medical Center, Los Angeles, CA
Background: Our objective was to evaluate the range of programmable parameters of
the Conor Medsystems MedStent™ loaded with lipophilic paclitaxel (PXL) in an in vitro
elution experiment. We examined: 1) spatial homogeneity, 2) the breadth of multiple tem-
poral and directional kinetic profiles, and 3) simultaneous combination of PXL with water
soluble 2-chlorodeoxyadenosine (CDA), a potent macrophage inhibitor.
Methods: Stents (9 formulations of 4 stents each) were immersed in aliquots of agitated
N, N-diethylnicotinamide, and released drug was measured by HPLC for up to 30 days.
Results: Spatial homogeneity for PXL varied by <3.5%. Graph A shows cumulative
release curves for 100% of the loaded PXL over 5-30 days. Seven unique first and zero
order temporal profiles were achieved with doses from 10-30 µg released either at the
vessel wall or at the wall and lumen. Graph B shows cumulative simultaneous release
from stents containing PXL and CDA.
Conclusions: This stent’s layered multi-drug/polymer inlay technology permits precise
control of spatial and temporal first and zero order pharmacokinetic elution profiles. A
novel feature is the ability to simultaneously deliver water soluble and lipid soluble combi-
nation chemotherapy from a simple polymer carrier structure. These capabilities are
undergoing further investigation in animal and human clinical trials. 
1139-48 Comparative Efficacy of Everolimus and Sirolimus 
Delivered via Polymeric Drug-Eluting Stents in the 
Porcine Coronary Model
Andrew J. Carter, Chi-An Wang, Jeff Royal, Leslie Coleman, Lori Gibson, Anastasia 
Rossi, Julie Booth, Russ Jones, Renu Virmani, Providence Heart Institute, Portland, OR, 
Armed Forces Institute of Pathology, Washington, DC
Background: Rapamycin and its analogs are now being coated on different stent plat-
forms, using different polymer matrices to prevent restenosis by impairing vascular
smooth muscle cell proliferation and neointimal formation.
Methods: We evaluated the feasibility and compared the efficacy of biostable polymeric
everolimus eluting stents and sirolimus eluting stents (Cypher™, Cordis, Inc.) in a por-
cine coronary model at 28 days. Cobalt chromium balloon expandable stents were
coated with a polymer containing everolimus (200 µg/cm2). Twelve pigs underwent place-
ment of 36 oversized (1.1:1) sirolimus (n=12), everolimus (n=12) and bare metal (cobalt
chromium, n=12) stents in the coronary arteries.
Results: Histological analysis revealed a similar mean percent stenosis between the
everolimus and sirolimus coated stents (20.8 ± 6.9% and 20.8 ± 7.6%, respectively). The
bare metal stents had a greater % area stenosis (26.8 ± 7.8), compared to both the
everolimus and sirolimus coated stents (p = 0.05). Neointimal thickness for vessels with
both the everolimus (0.13 ± 0.07 mm) and sirolimus (0.13 ± 0.08 mm) stents was also
reduced versus the bare metal stents (0.20 ± 0.07 mm, p < 0.04). There were no signifi-
cant differences in injury score between any of the groups.
Conclusion: Stent-based delivery of sirolimus and everolimus delivered via polymeric
matrices are equally effective in the suppression of neointimal formation at 28-days in the
porcine coronary model. Further study is necessary to document dose response and
long-term comparative effects of these drug eluting stents.
1139-49 Sirolimus-Eluting Stents: Pharmacokinetics in Blood, 
Vessel, and Myocardium in a Porcine Coronary Model
Fumiaki Ikeno, Lynn Bailey, Clark Willard, Gregory A. Kopia, Fermin Tio, John Dooley, 
Cordis Corporation, Warren, NJ, University of Texas, San Antonio, TX
Background: Sirolimus-eluting (SRL) stents have been shown to markedly reduce neoin-
timal formation. The purpose of this study was to define the initial in-vivo systemic phar-
macokinetics (PK) of SRL stents using the porcine coronary model.
Methods: Juvenile farm pigs underwent placement of SRL stents (153mg/stent) in the
LAD coronary artery. For the blood analysis study, SRL stents were implanted and blood
samples were drawn both through a catheter placed 1 cm distal to the stent and from the
jugular vein at 2, 5, 10, 15, 30, 45 minutes, 1, 2, 3, 4, 5, 6, 8, 24 hours. In a separate
study, SRL stents were implanted in each of three coronary arteries of juvenile farm pigs
which were sacrificed at 1, 3, 8, 30 days for assessment of sirolimus level in the stented
vessel, stent and myocardium and histomorphology. Bare metal stents were implanted as
the control.
Result: Both arterial and venous sirolimus levels increased in the first 60 minutes (peak:
3.73ng/ml in the LAD vs. 1.07ng/ml in vein at 60 minutes) and then declined, more rapidly
in the arterial samples than in the venous samples (0.84ng/ml in artery vs. 0.61ng/ml in
vein at 24 hours). Stent analysis demonstrated that 41±5% and 93±2% of total stent
sirolimus was released by 1 day and 30 days, respectively. Tissue sirolimus levels of
stented vessel segments peaked at 1 day following stent implantation (14.5±10.9ng/ml)
and then declined (1.79±0.90ng/mg at 30 days). The myocardium within and adjacent to
the stent borders, proximal and distal vessel and distant myocardium levels were less
than 2.0% of stented vessel level. At 30 days, %neointimal area was reduced by 57%
with SRL stents when compared with bare metal (48±14% vs. 27±13%, respectively;
p=0.0002).
Conclusion: These pharmacokinetic data demonstrate an initial separation between local
arterial and systemic blood levels which subsides by 24 hours. The peak sirolimus tissue
level occurs at 1 day while the peak blood level occurs at 60 minutes. Arterial and myo-
cardial tissue adjacent to or distant from the stent implanted vessel contains much less
sirolimus than the stented vessel. SRL stents can achieve effective local drug delivery to
target lesion with minimum drug concentration in surrounding tissue.
1139-50 Effect of Cerivastatin-Eluting Stent on Inflammatory 
Response, Platelet Deposition and Intimal Hyperplasia 
in a Porcine Coronary Model
Katsumi Miyauchi, Takayuki Yokoyama, Takatoshi Kasai, Shinya Okazaki, Hitoshi Satoh, 
Takeshi Kurata, Hiroyuki Daida, Juntendo University, Tokyo, Japan
Drug-eluting stents hold the promise of the dramatically reducing restenosis after coro-
nary intervention. Many experimental studies have shown that statins can inhibit SMC
proliferation, inflammation and platelet aggregation. Inflammatory reactions and platelet
deposition induced by stent were found to be positively associated with neointimal hyper-
plasia. We hypothesized that statin-eluting stent might inhibit the early and late inflamma-
tory response, platelet deposition and prevent neointimal hyperplasia in porcine coronary
arteries. Fifteen mm long stainless steel balloon expandable tubular stents were coated
with a thin layer of a biologic polymer matrix containing 300ug of cerivastatin. Cerivasta-
tin-loaded stents (n=20) and bare stents (n=20) were randomly deployed at a stent to
artery ratio of approximately 1.1 to 1.0 in the coronary arteries of 20 pigs. All animals sur-
vived without any adverse events. The lipid profile in both groups did not differ. Early
inflammatory cell infiltration and platelet doposition was evaluated with scanning electron
microscopy at 3 days after stenting and was significantly reduced in the treated vessels
compared to bare stent (mean inflammation score 0.45+0.55 vs. 2.88+0.99, p<0.01).
Histopathologic assessment after 28 days showed a significant decreased chronic
inflammatory cells surrounding the stent filaments and in adventitia of statin-coated
stents compared with bare stent. Quantitative intravascular ultrasound revealed that sta-
tin-coated stent decreased % diameter stenosis compared to bare stents (19% vs.42%,
p<0.01) wheras stent area was similar in both groups. Histomorphometry showed
increased lumen (2.66+0.35 vs 1.89+0.22, p<0.01) and reduced neointimal area
(0.65+0.22 vs 1.79+0.33, p<0.01 ) in statin-coated stent versus the bare metal stents
despite similar injury scores. Conclusion: Cerivastatin-eluting stents results in a signifi-
cantly decreased neointimal hyperplasia with decreased inflammatory response and
platelet deposition in porcine coronary arteries.
1139-51 Optimization of Pharmacokinetic Vectors With a 
Programmable Paclitaxel Eluting Stent
Joseph Aragon, Saibal Kar, Alexander Parisky, Colin Watanabe, Aamer Jamail, Frank 
Litvack, Neal Eigler, Cedars Sinai Medical Center, Los Angeles, CA
Background: The Conor MedStent™ loaded with Paclitaxel (PTX) can be programmed
from a multiparameter matrix of dose, temporal release profiles (order, duration), and
release pathways (lumen, mural (M), or bidirectional(BI)).Any set of parameters deter-
mine a unique pharmacokinetic vector (PKV). The goal of this study was to examine the
effects of widely differing PKVs on 30 day restenosis in a porcine model of stent injury.
Methods: Stents with 5 PKVs comprising doses 10 or 30 ug, zero order release for 10 or
30 days, and release pathways M and BI, were compared with bare metal and polymer-
loaded control stents in 55 coronary segments implanted in 21 pigs.
Results: Late loss (LL) in bare and polymer stents was 0.84±0.63 and 0.96±0.54 mm,
respectively (p=NS). There was no difference in balloon/artery ratio between groups,
(0.98 +/-0.32 p=NS). All PKVs reduced late loss (LL) vs. controls (Figure). PKV 30 ug
PTX, 10 day zero order BI release had the greatest reduction in LL (p<.00001).
Conclusions: We found that a dose, release profile and pathway that performed best
among 5 PKVs. Starting with large scale changes, an iterative process can be developed
to choose the best PKV.
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1139-52 Biolimus A9: A New Generation Rapamycin Analogue 
Inhibits Intimal Hyperplasia in a Porcine Model
Saibal Kar, Joseph Aragon, Alexander Paresky, Fermin Tio, John Shulze, Ronald Betts, 
Neal Eigler, Frank Litvack, Cedars Sinai Medical Center, Los Angeles, CA
Background: Biolimus A9 is a novel, rapamycin analogue especially designed for drug
eluting stent application . Biolimus A9 is developed with the intent of optimizing release
kinetics and tissue partitioning while maintaining the inhibitory properties of Sirolimus on
smooth muscle cells.
Methods: Nine Bare metal(B) and 9 BiolimusA9(B9) coated stents were evaluated in 28
day ovestretch porcine model. The drug delivery polymer was thin layer bio-resorbable
Poly-lactic-acid. The average balloon artery ratio was 1.18±0.3. At sacrifice coronary
angiography and histologic analysis was performed for each stented vessel.
Results: The results are tabulated in Table 1. There was no difference of injury in both
groups. There was 50% reduction of area stenosis by the B9 coated stent(p=0.001). His-
tology, showed near complete endotheliazation in both control and A9 groups with a only
a slight increase in fibrin content in the B9 group.Conclusions; BiolimusA9 delivered via
bioresorbable polymer coated stent inhibits intimal hyperplasia in a porcine model. There
is normal healing of treated arteries at 28days and no inflammation as compared to con-
trols.A first-in man clinical trial has been intiated
1139-53 The Long-Term Clinical Results of a Platelet 
Glycoprotein IIb/IIIa Receptor Blocker (Abciximab: 
ReoPro®) Coated Stent in Patients With Coronary Artery 
Disease
Weon Kim, Myung Ho Jeong, Young Keun Ahn, Ju Han Kim, Young Joon Hong, Jeong 
Gwan Cho, Jong Chun Park, Jung Chaee Kang, Chonnam National University Hospital, 
GwangJu, South Korea
Background : Previously we reported the inhibition of coronary restenosis with Abcix-
imab(ReoPro®)-coated stent in a porcine model. ReoPro® inhibits platelet aggregation,
the proliferation of vascular smooth muscle cells and inflammatory reaction.
Methods : We performed a prospective randomized trial to compare two types of stents
for the revascularization in native coronary artery. The primary effective end points were
major adverse coronary events (MACE): cardiac death, acute myocardial infarction, tar-
get vessel revascularization (TVR), restenosis at 6-month clinical and angiographic fol-
low-up.
Results : One hundred fifty-five patients were enrolled between Aug, 2001 and Jun,
2003. Mean ages (56.0±10.0 vs. 56.9±10.8 years), baseline diameter stenosis and mini-
mal luminal diameter were not different between the two groups. There was one myocar-
dial infarction and revascularization during hospital stay in control stent group. During
clinical follow-up, there were two myocardial infarctions in control group. Follow-up coro-
nary angiogram was done 62.3% (48/77) in coated and 65.4% (51/78) in control groups.
Diameter stenosis and late loss were significantly less in the ReoPro®-coated stent group
compared with controls (16.4±5.8% vs. 34.3±6.1%, p=0.009; and 0.33±0.28 mm vs.
0.88±0.41 mm; p=0.002). The restenosis and TVR rates of ReoPro®-coated stent were
relatively lower compared with control stent [14.6%(7/48) vs. 29.4%(15/51), p=0.062; and
9.2%(7/76) vs. 14.7%(11/75); p=0.327].
Conclusion : A ReoPro®-coated stent is safe and may be effective in the prevention of
coronary restenosis.
1139-54 Nitric Oxide Through Biodegradable Layer Elective 
Study for Safety and Efficacy (NOBLESSE): Final 
Results From the South American Study Arm
Xiaoshun Liu, Costantino Costantini, Hugo Londero, Hans Bonnier, Ivan De Scheerder, 
The NOBLESSE Investigators, University Hospitals Leuven, Leuven, Belgium
Background: Oxygen free radical scavengers may play a significant role in preventing
neointimal hyperplasia after stent implantation. The Blue Medical TEMPO coronary stent
is characterized by its particular biodegradable PEA coating conjugated with tempamine,
a potent antioxidant substance. Pre-clinical work showed a similar tissue response and
reduced intimal hyperplasia in a porcine coronary stent model using this stent. The aim of
this study was to evaluate the acute safety and efficacy of the TEMPO loaded Blue Med-
ical stent implanted in patients with de-novo single vessel disease.
Methods: This is a multinational, multicenter, 2 armed phase III trial. 45 patients treated
with an intermediate dose (50%) of tempamine loaded on the Blue Medical stent from 2
South American study sites are presented: 64% were male, average age 61 (range 37 -
86) 38% had lesion type B2 or C. One 14 mm or 18mm long stent was used. Minimal
lumen diameter (MLD) and % diameter stenosis (DS) were measured. The primary end-
points are 4m in-stent %DS and late loss determined by QCA. The secondary endpoints
are binary restenosis rate at 4m follow-up and 30 days, 60 days and one year major
adverse cardiac events (MACE) defined as death, MI, CABG & target vessel revascular-
ization.
Results: All the stent implantations were successful except one that resulted in a distal
dissection, treated by an additional coated stent implantation. Two patients were
excluded because of violation of the inclusion and/or exclusion criteria. There was no
MACE at 30 days and 60 days f-up. TLR occurred in 2 patients during the 4m f-up. 4m
angiographic f-up rate was obtained in 98%. QCA: mean reference diameter: 3.01±0.29
mm, % Ds was 64.01±12.20% before, 8.40±4.01% after stent implantation and
30.37±17.03 % at 4m f-up. Late loss was 0.69±0.52. Four patients developed an in-stent
restenosis at 4m resulted in a binary restenosis rate of 9.52%. Final 12m clinical f-up will
be presented
Conclusion: This short term and 4 month results show that implantation of a tempamine
loaded Blue Medical stent is feasible and safe. QCA data showed a low late loss and
binary restenosis rate, therefore suggesting a beneficial effect on neointimal hyperplasia
and in-stent restenosis.
1139-55 Optimal Geometry Is Still Important With Sirolimus-
Eluting Stents: Incomplete Stent Expansion as a Risk 
for Target Lesion Revascularization
Junya Ako, Yoshihiro Morino, Mitsuyasu Terashima, Yasuhiro Honda, Shinjo Sonoda, 
Martin B. Leon, Jeffrey W. Moses, Paul G. Yock, Peter J. Fitzgerald, The SIRIUS 
Investigators, Stanford University, Stanford, CA, Lenox Hill Hospital, New York, NY
Background: Despite the striking reduction in neointimal hyperplasia seen with sirolimus
eluting stents (SES), target lesion revascularization (TLR) has not been completely elimi-
nated. The aim of this IVUS substudy was to clarify procedure-related risk factors for TLR
in sirolimus-eluting stents.
Methods and Results: Angiographic and IVUS data were obtained from SIRIUS, a pro-
spective, randomized, multicenter clinical trial comparing SES (sirolimus-eluting Bx
VELOCITY, Cordis) and bare metal stent (BMS). Post-procedure IVUS measurements in
SES were available in 108 cases. Stent expansion was defined as minimum stent area
(MSA) divided by reference LA. There were 6 TLR cases in SES in this patient cohort.
Table summarizes comparisons between TLR and non-TLR cases. Angiographic lesion
length was longer in TLR cases. With respect to procedure-related factors, TLR cases
had lower maximal pressure, smaller % expansion, and a trend toward smaller MSA.
Conclusions: Incomplete stent expansion may be a risk factor for TLR in sirolimus-elut-
ing stents. Proper mechanical stent deployment to achieve adequate lumen geometry
may further improve the clinical success of this technology. 
1139-56 Impact of Stent Implantation Techniques on Stent Edge 
Neointimal Hyperplasia Following Sirolimus-Eluting 
Stenting
Mieke van den Heuvel, Mamoo Nakamura, Junya Ako, Yoshihiro Morino, Yasuhiro 
Honda, Martin B. Leon, Jeffrey W. Moses, Paul G. Yock, Peter J. Fitzgerald, Alan C. 
Yeung, Stanford University, Palo Alto, CA
Background: IVUS substudy of the SIRIUS trial showed a tendency for neointimal hyper-
plasia (NI) to develop at stent edges after sirolimus-eluting Bx VELOCITY stent (SES)
implantation. However, predictors for this phenomenon have not been clarified. In this
study, we examined the potential risk factors including procedural demographics for stent
Histomorphometric Analysis of the Bare and Biolimus A9 stents
Bare Stent(9) Biolimus A9(9) p value
Injury Score 0.30+ 0.10 0.30+ 0.12 NS
Intimal Hyperplasia(Um) 238 + 24 152 + 14 0.004
Area Stenosis(%) 38 20 0.001
No-TLR TLR P
B/A ratio 1.0±0.1 0.9±0.2 NS
Nominal balloon diameter, mm 3.1±0.5 2.8±0.3 NS
Maximum Pressure, atm 17.0±2.7 14.7±1.0 0.03
Lesion Length, mm 14.2±5.2 18.8±5.0 0.04
MLD, mm 2.7±0.4 2.6±0.2 NS
% diameter stenosis 3.5±8.0 6.4±7.5 NS
Reference lumen area, mm2 6.6±2.3 6.5±0.8 NS
MSA, mm2 6.0±1.8 4.6±0.6 0.07
% Stent Expansion 94±22 71±15 0.03
